1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Visugromab (CTL-002): new trials by email Literature Review of Visugromab (CTL-002) trials Research Report on Visugromab (CTL-002)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-09-22 |
| Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor | Phase 2 | Completed | CatalYm GmbH | 31 | 2023-09-06 | 2026-08-19 |
| First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) visugromab (CTL-002), nivolumab - Solid Tumor, Adult | Phase 1 / Phase 2 | Active not recruiting | CatalYm GmbH | 199 | 2020-12-09 | 2026-08-19 |
Anorexia (1) · Cachexia (1) · Neoplasms (1) · Urinary Bladder Neoplasms (1) · Weight Loss (1)
CatalYm GmbH (3)
Germany (2) · Italy (2) · Spain (2) · Switzerland (2) · Bulgaria (1) · Czechia (1) · France (1) · Norway (1) · Poland (1) · Romania (1) · United Kingdom (1) · United States (1)
Felix Lichtenegger, MD (1) · Frank Hermann, MD (1)